NASDAQ:INSY - Insys Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.59 +0.18 (+4.08 %)
(As of 03/25/2019 04:00 PM ET)
Previous Close$4.41
Today's Range$4.2786 - $4.63
52-Week Range$3.35 - $11.65
Volume361,963 shs
Average Volume1.13 million shs
Market Capitalization$341.62 million
P/E Ratio-3.30
Dividend YieldN/A
Beta2.56
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INSY
Previous SymbolNASDAQ:NEOL
CUSIPN/A
Phone480-500-3127

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.08 million
Book Value($0.58) per share

Profitability

Net Income$-124,510,000.00
Net Margins-151.79%

Miscellaneous

EmployeesN/A
Market Cap$341.62 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics shares split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics Inc (NASDAQ:INSY) announced its earnings results on Thursday, March, 7th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.08. The specialty pharmaceutical company had revenue of $16.36 million for the quarter, compared to analyst estimates of $17.93 million. Insys Therapeutics had a negative return on equity of 1,430.52% and a negative net margin of 151.79%. View Insys Therapeutics' Earnings History.

When is Insys Therapeutics' next earnings date?

Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Insys Therapeutics.

What price target have analysts set for INSY?

6 equities research analysts have issued 12 month price targets for Insys Therapeutics' shares. Their forecasts range from $4.00 to $11.00. On average, they anticipate Insys Therapeutics' stock price to reach $7.28 in the next year. This suggests a possible upside of 58.6% from the stock's current price. View Analyst Price Targets for Insys Therapeutics.

What is the consensus analysts' recommendation for Insys Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insys Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insys Therapeutics.

Has Insys Therapeutics been receiving favorable news coverage?

Media stories about INSY stock have trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insys Therapeutics earned a coverage optimism score of -1.1 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term.

Are investors shorting Insys Therapeutics?

Insys Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 10,176,191 shares, an increase of 19.2% from the January 31st total of 8,534,908 shares. Based on an average daily volume of 1,500,292 shares, the short-interest ratio is currently 6.8 days. Currently, 38.0% of the company's stock are sold short. View Insys Therapeutics' Current Options Chain.

Who are some of Insys Therapeutics' key competitors?

What other stocks do shareholders of Insys Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insys Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Canopy Growth (CGC), Zynerba Pharmaceuticals (ZYNE), Micron Technology (MU), Alibaba Group (BABA), Incyte (INCY), Puma Biotechnology (PBYI), NVIDIA (NVDA) and BioMarin Pharmaceutical (BMRN).

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:
  • Mr. Saeed Motahari, CEO, Pres & Director (Age 53)
  • Mr. Andrew G. Long, Chief Financial Officer
  • Mr. Franc Del Fosse, Sr. VP of Corp. Affairs (Age 47)
  • Dr. Danny L. Tuck, Sr. VP of Quality Operations
  • Mr. Mark E. Nance, Chief Legal Officer & Gen. Counsel

Who are Insys Therapeutics' major shareholders?

Insys Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.61%), ETF Managers Group LLC (1.98%), Norges Bank (0.84%), Millennium Management LLC (0.73%), D. E. Shaw & Co. Inc. (0.69%) and Northern Trust Corp (0.48%). Company insiders that own Insys Therapeutics stock include Brian Tambi, John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Institutional Ownership Trends for Insys Therapeutics.

Which major investors are selling Insys Therapeutics stock?

INSY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and Northern Trust Corp. View Insider Buying and Selling for Insys Therapeutics.

Which major investors are buying Insys Therapeutics stock?

INSY stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Norges Bank, D. E. Shaw & Co. Inc., Raging Capital Management LLC, Millennium Management LLC, Squarepoint Ops LLC, Two Sigma Investments LP and Two Sigma Advisers LP. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy shares of Insys Therapeutics?

Shares of INSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of INSY stock can currently be purchased for approximately $4.59.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $341.62 million and generates $82.08 million in revenue each year. The specialty pharmaceutical company earns $-124,510,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

What is Insys Therapeutics' official website?

The official website for Insys Therapeutics is http://www.insysrx.com.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected]


MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  387 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  683
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel